natalizumab elan pharma
elan pharma international ltd. - natalizumab - morbus crohn - immunostimulants, - die behandlung von mäßig bis schwer aktiver morbus crohn bei der reduzierung der anzeichen und symptome, und die induktion und aufrechterhaltung der anhaltende response und remission bei patienten, die nicht geantwortet haben, trotz einer vollständigen und adäquaten therapie mit einem kortikosteroid und immunsuppressivum; oder intolerant sind oder medizinische kontraindikationen für solche therapien.
tysabri 300 mg konzentrat zur herstellung einer infusionslösung
biogen switzerland ag - natalizumabum - konzentrat zur herstellung einer infusionslösung - natalizumabum 300 mg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 15 ml corresp. natrium 52 mg. - multiple sklerose - biotechnologika
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 und 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
tysabri
biogen netherlands b.v. - natalizumab - multiple sklerose - selektive immunsuppressiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 und 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
tysabri 150 mg/ml injektionslösung in einer fertigspritze
biogen switzerland ag - natalizumabum - injektionslösung in einer fertigspritze - natalizumabum 150 mg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.45 mg. - multiple sklerose - biotechnologika
gilenya 0.5 mg kapseln
novartis pharma schweiz ag - fingolimodum - kapseln - fingolimodum 0,5 mg zu fingolimodi hydrochloridum, mannitolum, magnesium stearas, kapselhülle: e 172 (gelb), e 171, gelatine, drucktinte: lacca, alcohol isopropylicus, alcohol butylicus, propylenglycolum, aqua purificata, ammoniae lösung 28 pro hundert, kalii hydroxidum, e 172 (schwarz), e 172 (gelb), e 171, dimeticonum für eine kleine box. - multiple sklerose - synthetika
gilenya 0.25 mg kapseln
novartis pharma schweiz ag - fingolimodum - kapseln - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, mannitolum, hydroxypropylcellulosum, hydroxypropylbetadexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum pro capsula. - multiple sklerose - synthetika
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimethylfumarat - multiple sklerose, schubförmig-remittierender - immunsuppressiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
fingolimod-mepha teva 0.5 mg kapseln
mepha pharma ag - fingolimodum - kapseln - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium 0.045 mg, kapselhülle: e 171, e 172 (flavum), gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum, pro capsula. - multiple sklerose - synthetika
fingolimod basics 0,5 mg hartkapseln
basics gmbh (8036279) - fingolimodhydrochlorid - hartkapsel - 0,5 mg - teil 1 - hartkapsel; fingolimodhydrochlorid (30117) 0,56 milligramm